Novartis To Slash 1960 US Jobs; Glenmark Projects 20% Growth In Sales
Mon, 01/16/2012 - 08:29 | 
Drug manufacturer Novartis will slash around 1,960 jobs in US during 2012 in expectancy of lower sales for two of its high blood pressure medications.
Savient Pharmaceuticals has roped in David Veitch President of Savient Europe with effect from January 16, 2012.
Glenmark Pharmaceuticals projects sales of its speciality biz, which concentrates on branded products, to develop by about 20% in the Indian market by the
coming three years (2015).
Fleming Pharmaceuticals has sold four of its well known brands, comprising Ocean nasal spray, to a division of a Canadian drug firm.
Tags: Novartis Recalls Excedrin; Endo Pharma Inks Licensing Deal With BioDelivery
Swiss pharma giant Novartis stated that it was recalling four different medications sold over the counter in the US market following reports of a malfunction at one of its facilities.
Synta Pharmaceuticals is offering 7 million scrips of common stock to the public, with the prospective of making net income of $28.6 million, the company said.
Savient Pharmaceuticals declared that a product-specific billing system, or lasting J-code, for KRYSTEXXA® (pegloticase) became accessible on January 1, 2012.
Endo Pharmaceuticals has decided to pay around $180 million for licensing rights
